Overexpression of LBD-lacking AR variants (e.g., AR-V7, and ARv567es) has been shown to promote prostate cancer growth both in cell lines and in mouse xenograft models under androgen-depleted conditions [5,14,15,16,21], presumably due to their androgen-independent activation of the AR signalling pathway. Here, AR is linked to prostate carcinoma.